Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 2/20 | 0.67 |
| ▸ | PRKCG | P05129 | 2/20 | 0.67 |
| ▸ | PRKCB | P05771 | 2/20 | 0.67 |
| ▸ | PRKCA | P17252 | 2/20 | 0.67 |
| ▸ | PRKCH | P24723 | 2/20 | 0.67 |
| ▸ | PRKCI | P41743 | 2/20 | 0.67 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.67 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.67 |
| ▸ | PRKCZ | Q05513 | 2/20 | 0.67 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.67 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.67 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL290985 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL28598698 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855849 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855744 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855768 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855786 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5447359 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL8855806 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL14560967 | 1.00 | PRKD3 (0.67) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| Hydrochloric Acid SCHEMBL25306967 | 0.98 | PRKD3 (0.65) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678163-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NAIL AND SKIN TINEA | Chang, Byeung Mo (KR) | 2026-01-14 | — | — | EP | claimed |
| WO-2024185956-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NAIL AND SKIN TINEA | 장병모 | 2024-09-12 | — | — | WO | claimed |
| CN-101374805-A | Organic derivatives, their salts and use for the control of phytopathogens | ISAGRO SPA (IT) | 2009-02-25 | — | — | CN | claimed |
| EP-4678163-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NAIL AND SKIN TINEA | Chang, Byeung Mo (KR) | 2026-01-14 | — | — | EP | disclosed |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SKINVISIBLE PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12472140-B2 | Composition and method for transdermal delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC) | Ovation Science Inc. (CA) | 2025-11-18 | — | — | US | disclosed |
| WO-2024185956-A2 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NAIL AND SKIN TINEA | 장병모 | 2024-09-12 | — | — | WO | disclosed |
| US-20230138946-A1 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) | OVATION SCIENCE INC (CA) | 2023-05-04 | — | — | US | disclosed |
| CN-115636848-A | Method for synthesizing phosphorylcholine compounds by one-pot method | 深圳翰宇药业股份有限公司 | 2023-01-24 | — | — | CN | disclosed |
| US-11439602-B2 | Composition and method for transdermal delivery of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) | Ovation Science Inc. (CA) | 2022-09-13 | — | — | US | disclosed |
| US-20210251912-A1 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC) | Ovation Science Inc. (CA) | 2021-08-19 | — | — | US | disclosed |
| WO-2015120447-A1 | METHODS OF NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20150225713-A1 | METHODS FOR NUCLEIC ACID CAPTURE | ZYMO RESEARCH CORPORATION | 2015-08-13 | — | — | US | disclosed |
| CN-101374805-B | Organic derivatives, their salts and use for the control of phytopathogens | ISAGRO SPA | 2013-10-16 | — | — | CN | disclosed |
| CN-101374805-A | Organic derivatives, their salts and use for the control of phytopathogens | ISAGRO SPA (IT) | 2009-02-25 | — | — | CN | disclosed |
| CN-101326919-A | Novel surfactants and preparation | MONSANTO TECHNOLOGY LLC (US) | 2008-12-24 | — | — | CN | disclosed |
| US-20070154546-A1 | Sustained release pharmaceutical compositions | INTERNATIONAL MEDICATION SYSTEMS, LIMITED | 2007-07-05 | — | — | US | disclosed |
| CN-1444451-A | Novel surfactants and formulations | MONSANTO TECHNOLOGY LLC (US) | 2003-09-24 | — | — | CN | disclosed |
| US-5614510-A | AMMONIUM SALTS | PERSTORP AB (SE) | 1997-03-25 | — | — | US | disclosed |
| WO-1993016705-A1 | A PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY OF INOSITOL PHOSPHATE | PERSTORP AB (SE) | 1993-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070154546-A1 | Sustained release pharmaceutical compositions | PLA2G2C, PLTP, F12 | PRKD3 3946/4885PRKCG 2762/4885PRKCB 3837/4885 |
| US-20250352559-A1 | Transdermal Delivery Composition for Delivery of at least one Glucose Controlling Agent, and Method of Delivering at least one Glucose Controlling Agent | SLC2A1, SLC2A4, SLC2A8 | PRKD3 4836/4885PRKCG 2805/4885PRKCB 2547/4885 |
| US-20210251912-A1 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and 9-Tetrahydrocannabinol (THC) | FAAH, CNR2, CNR1 | PRKD3 3087/4885PRKCG 804/4885PRKCB 1039/4885 |
| US-12472140-B2 | Composition and method for transdermal delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC) | DSG1, CNR2, CNR1 | PRKD3 3145/4885PRKCG 933/4885PRKCB 1195/4885 |
| US-11439602-B2 | Composition and method for transdermal delivery of cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) | FAAH, CNR2, CNR1 | PRKD3 3029/4885PRKCG 768/4885PRKCB 952/4885 |
| US-20230138946-A1 | Composition and Method for Transdermal Delivery of Cannabidiol (CBD) and Tetrahydrocannabinol (THC) | DSG1, CNR2, CNR1 | PRKD3 3145/4885PRKCG 933/4885PRKCB 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.